Yatai pharm(SZ:002370)2022-12-06 23:56Group 1: Business Overview - The main business of Zhejiang Apac Pharmaceutical Co., Ltd. includes the research, production, and sales of chemical preparations, chemical raw materials, and diagnostic reagents, with chemical preparations being the primary source of revenue [3]. - The company currently has approximately 30-40 products on the market, focusing on optimizing product structure and increasing the proportion of non-antibiotic specialty products [3]. - Future collaboration with Xinshengyuan will enhance drug screening research, consistency evaluation, and clinical trials, aiming to expand overall business scale and improve profitability [3]. Group 2: Strategic Goals - The company plans to leverage its capital platform for mergers and acquisitions in high-value sectors such as new drug development and high-end medical devices, aligning with its strategic goal of industrial transformation and upgrading [3]. - The management is committed to improving operational performance despite challenges in predicting future business performance due to bidding conditions [4]. Group 3: Market Position and Future Plans - Xinshengyuan, as a platform-based CRO, emphasizes efficient GRDP management and aims to build a network of clinical teams and hospitals for consistency evaluation, which is a key focus for future business development [4]. - The company acknowledges its late entry into the market and is considering the development of new fields and products in the future [5]. Group 4: Shareholder and Management Insights - The major shareholder currently has no intention of increasing or decreasing their stake, and there are no plans for equity incentives for management [4].